组织工程与重建外科杂志

组织工程与重建外科杂志 ›› 2016, Vol. 12 ›› Issue (6): 381-384.doi: 10.3969/j.issn.1673-0364.2016.06.015

• 综述 • 上一篇    下一篇

黑色素瘤抗体治疗研究进展

赵辉，孙梦妍，王宇翀，薛春雨   

  1. 第二军医大学附属长海医院整形外科
  • 发布日期:2020-07-23

Research Progress of Antibody Therapy in Melanoma

ZHAO Hui,SUN Mengyan,WANG Yuchong,XUE Chunyu   

  1. Department of Plastic Surgery, Changhai Hospital, Second Military Medical University;
  • Published:2020-07-23
  • Contact: 上海市科学技术委员会科研计划项目（13jc1401403）；第二军医大学青年启动基金课题（2013qn08）

摘要： 黑色素瘤是一类起源于神经嵴黑色素细胞的高度恶性肿瘤,易发生远处转移,转移性黑色素瘤患者的预后很差。近年来,免疫治疗逐渐成为黑色素瘤治疗的新方向,越来越多的免疫药物被用于临床治疗。其中,对T细胞肿瘤免疫研究日益深入,多个有治疗意义的T细胞调节通路位点和共刺激分子被发现,并被用于加强对黑色素细胞瘤的免疫反应。本文就两种单克隆抗体,即程序死亡分子1(PD-1)和抗细胞毒性T淋巴细胞相关抗原4(CTLA-4),以及两种共刺激分子OX40和4-1BB在近年的研究进展进行综述。

关键词: 黑色素瘤, 单克隆抗体, 共刺激分子

Abstract: Malignant melanoma is a kind of highly malignant tumor originated from neural crest melanin ceils, prone to distant metastases, the prognosis of patients with metastatic malignant melanoma is poor. Immunotherapy in recent years gradually becomes the new direction for treating malignant melanoma, a growing number of immune drugs are used in clinical treatment. There has been a revolution in the clinical management of melanoma with the development of multiple antibodies that influence T cell regulatory pathways, including checkpoint inhibition and co-stimulation. In this paper, two monoelonal antibodies （PD-1 and CTLA-4）, and two costimulatory pathways （OX40 and 4-1BB） were reviewed to describe the recent progress for treating melanoma.

Key words: Malignant melanoma, Monoclonal antibody, Costimulatory factor

中图分类号: